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ABSTRACT 
Purpose 
To develop and demonstrate a novel tumor shell feature for predicting distant failure in non-small cell lung cancer 
(NSCLC) and cervical cancer (CC) patients.  
Patients and Methods 
The shell predictive model was constructed using pre-treatment positron emission tomography (PET) images from 
48 NSCLC patients received stereotactic body radiation therapy (SBRT) and 52 CC patients underwent external 
beam radiation therapy and concurrent chemotherapy followed with high-dose-rate intracavitary brachytherapy. A 
shell feature, consisting of outer voxels around the tumor boundary, was extracted from a series of axial PET slices. 
The hypothesis behind this feature is that non-invasive and invasive tumors may have different morphologic patterns 
in the tumor periphery, in turn reflecting the differences in radiological presentations in the PET images. The shell’s 
utility was evaluated by the support vector machine (SVM) classifier in comparison with intensity, geometry, gray 
level co-occurrence matrix (GLCM)-based texture, neighborhood gray tone difference matrix (NGTDM)-based 
texture, and a combination of these four features.  The results were assessed in terms of accuracy, sensitivity, 
specificity, and the area under the receiver operating curve (AUC).  
Results 
For NSCLC, the AUC achieved by the shell feature was 0.82 while the highest AUC achieved by the other features 
was 0.76. Similarly, for CC, the AUC achieved by the shell feature was 0.83 while the highest AUC achieved by the 
other features was 0.76. Also, the difference in performance between shell and the other features was significant (P 
< 0.005) in all cases. 
Conclusions 
We propose a boundary-based shell feature that correlates with tumor metastasis. The shell feature showed better 
predictive performance than all the other features for distant failure prediction in both NSCLC and CC. 
 
INTRODUCTION 
       Distant failure occurs when malignant tumor 
cells metastasize to distant organs,1,2 causing up to 90% 
human cancers-associated deaths.3,4 Stereotactic body 
radiation therapy (SBRT) is widely used in patients 
with early stage medically inoperable non-small cell 
lung cancer (NSCLC), achieving 85-95% local 
control rates5-7. Despite the high local control rates, 
distant failure is still common, with 3-year and 5-year 
distant relapse rates of 22% and 31%, respectively.8-
10 Similarly, in patients with locally advanced 
cervical cancer (CC),  even receiving external beam 
radiation therapy (EBRT) with concurrent 
chemotherapy and intracavitary brachytherapy (ICBT) 
as the recommended therapy,11 at least 20% of them 
still develop distant metastases; 12,13 and in the 
patients with positive para-aortic involvement, the 
rate is more than  40%.14,15 Therefore, predicting 
distant failure in high risk patients is essential to 
achieve better treatment outcomes with intensified 
treatment modalities.   
       Although many of the mechanisms that govern 
metastasis are still unclear, the tumor 
microenvironment is known to regulate tumor 
evolution toward metastasis,16,17 as shown for 
cervix,18,19 lung,20,21 colon cancer among other cancer 
types.22,23  
       A correlation was found between the 
microenvironment and distant failure, 24 typically 
exemplified by the theory of epithelial-to-
mesenchymal transition (EMT). In this process, a 
portion of cancer cells located at the tumor edges 
may acquire cancer stem cell (CSC)-like traits typical 
of metastasis, including self-renewal, tumor-
originating, invasiveness, and elevated apoptosis 
resistance; these cancer cells depart from the main 
tumor and initiate metastasis, leading to junctional 
alterations and spatial heterogeneity.25-28 This cellular 
invasion process was simulated by a hybrid 
multiscale mathematical model, showing that 
invasive tumor cells first developed within the tumor 
and later penetrated the tumor edge to form 
metastases.29  
       In addition to EMT and CSCs, tumor budding 30 
is another factor contributing to invasion and 
correlating with worse outcomes in colon 
cancer,22,31,32 lung cancer, 33-36cervix cancer37 among 
others.38-41 In tumor budding, isolated or clustered 
small malignant cells are close to the tumor edge. 
Literature reviews have reported that tumor buds can 
be a realization of CSC and an exhibition of the EMT 
process,42,43 suggesting tumor budding as an 
independent prognostic factor. 37,44,45  
       Tumor islands were also observed on tumor 
edges. 46 In lung cancer, tumor islands are large nests 
of malignant cells connected with one another and 
with primary tumors in alveolar spaces, slightly near 
the tumor border; they also have been associated with 
poor prognosis.47 Studies were expanded by 
discovering spread through air space (STAS), a 
phenomenon of aggressive cells within air spaces 
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closely beyond the edge of the tumor. STAS has been 
recognized an important pattern of invasion, 48-50 and 
was approved by the 2015 World Health 
Organization as an independent metastatic predictor 
of lung cancer within the lung classification system. 
51  
       These findings suggest that the appearance of the 
interface between tumor and normal tissue may 
provide phenotypic information related to metastatic 
potential that would enable the development of 
prognostic and predictive models. This application is 
enabled by radiomics, which can extract quantitative 
radiologic imaging features related to the aforesaid 
cellular phenotype, i.e., EMT-induced CSC changes, 
tumor budding, tumor islands, and STAS. 52 
Furthermore, because of its potential correlation with 
pathologic morphology,53-56 positron emission 
tomography (PET) has been studied to predict the 
pathologic outcome of therapy in various cancers, 
including lung,57-60 cervix, 61,62 and other cancers.63-65 
These studies have revealed PET as a promising 
quantitative reflection of the pathologic heterogeneity 
at the tumor edges.  
        We developed the tumor shell, a radiomics 
feature that characterizes the tumor periphery and its 
correlation with distant failure. We demonstrated its 
ability in predicting treatment response for patients 
receiving SBRT for early stage NSCLC and for 
patients receiving EBRT and concurrent 
chemotherapy followed by high-dose-rate ICBT in 
stage IB-IVA CC. 
 
PATIENTS AND METHODS 
Patients 
       Our study was conducted at our institution, on 
two cohorts of patients approved by Institutional 
Review Board: (1) 48 early stage IA and IB NSCLC 
patients treated with SBRT from 2006 to 2012 (28 
males and 20 females; mean age, 70.58 ± 9.84 years; 
range, 54 to 90 years); (2) 52 stage IB-IVA cervix 
cancer patients without para-aortic node involvement, 
treated with EBRT and concurrent chemotherapy 
followed by high-dose-rate ICBT from 2009 to 2012 
(mean age, 47.10 ± 11.82 years; range, 26 to 72 
years). In the NSCLC dataset, the total number of 
PET slices for each patient varied from 274 to 355, 
with 2.00 to 5.00-mm slice thickness and 4.0×4.0-
mm or 5.0×5.0-mm pixel spatial resolution. 
Therefore, all slices were interpolated with the 
smallest slice thickness of 2.0 mm and spatial 
resolution of 4.0×4.0 mm to achieve a consistent 
format. In the CC dataset, all slices were used 
directly without interpolation since they had the same 
5.00-mm slice thickness and 4.0×4.0-mm pixel 
spatial resolution. Before tumor analysis, the raw 
PET data were converted to standard uptake values 
(SUV).  
Tumor Analysis 
       For each patient, slices containing primary 
tumors were selected for analysis. In the NSCLC 
cohort, tumors were segmented automatically, with 
the middle location slice segmented by the object 
information based interactive segmentation method 
(OIIS) 66and other slices segmented by the OTSU 
method.67 In the CC cohort, the region of interest that 
incorporated the entire tumor was delineated 
manually by a radiation oncologist with 4 years’ 
experience and reviewed by another radiation 
oncologist with 19 years’ experience. In the NSCLC 
cohort, the number of selected slices originally 
ranged from 5 to 17, and zero padding was used for 
patients with slice numbers less than 17. Therefore, 
after interpolation to the smallest slice thickness of 
2.0 mm, all patients had 42 slices. Meanwhile, 
because the greatest in-plane tumor diameter in all 
the patients’ slices was 13 pixels, a patch of 17 × 17 
pixels was cropped around the tumor center in each 
slice, resulting in a cube size of 17 × 17 × 42 for each 
patient. A volume size of 29 × 29 × 40 was used for 
each patient in the CC cohort. All features were 
computed on cropped PET cubes. 
Tumor Shell Feature Construction 
       The shell feature was extracted from the voxels 
around the tumor boundaries in a series of axial PET 
slices. The workflow of the shell feature construction 
is illustrated in Fig 1. The top row shows slices of the 
tumor (outlined in the red windows) in axial 
sequence (Fig 1). As displayed in the second row 
(Fig 1), the patches that include the delineated tumor 
were cropped from the corresponding slices above 
and used to compute the shell feature. By 
thresholding the patches above zero, binary mask 
images were obtained to represent the specific tumor 
region. By using the mask images of every two 
adjacent patches, a number of difference images were 
derived. As expected, a difference image was 
generally the outer region of the tumor. By adding up 
the difference images, referred to as sub-shells in the 
third row in Fig 1, the shell feature was formed and 
used to represent the holistic heterogeneity of voxels 
in the boundary of the entire tumor volume.        The sub-shell sequence  Ψሺݐሻ is defined as: 
Ψሺݐሻ ൌ
൜൫ܯሺݐሻ െܯሺݐ െ 1ሻ൯ ∘ ൫ܲሺݐሻ െ ܲሺݐ െ 1ሻ൯, ݐ ൒ 2૙,																																																																								, ݐ ൌ 1 ,                                  
(1) 
where ܲሺݐሻ denotes a patch sequence and ܯሺݐሻ is the 
matching binary mask image sequence that indicates 
the region of the tumor, the symbol  ∘ indicates the 
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hadamard product and	ݐ is the patch (slice) number. 
When ݐ ൌ 1,Ψሺݐሻ is a zero matrix ૙. The element in  
Ψሺݐሻ  is either greater than (when corresponding 
elements in ܯሺݐሻ and ܯሺݐ െ 1ሻ are 0, 1 or 1, 0) or 
equal to zero (when corresponding elements in ܯሺݐሻ 
and ܯሺݐ െ 1ሻ are 0, 0 or 1, 1). Thus, each sub-shell 
partially describes the heterogeneous architecture of 
the tumor edge in an image where the higher SUV 
value pixels appear brighter. Examples of sub-shells 
are presented in Fig 1. 
       To represent the heterogeneity of the whole 
tumor border, for each patient ݇  the shell feature  
ܵሺ݇ሻ  is constructed by successively accumulating 
sub-shells together and can be written as: 
ܵሺ݇ሻ ൌ ∑ Ψሺݐሻ௡௧ୀଶ  .                     (2)                                                                                                                        
where n is the total slice amount with ݊ ൌ 42 in the 
NSCLC cohort and ݊ ൌ  40  in the CC cohort. The 
strength of the shell feature is the use of a compact, 
yet comprehensive description that captures a 
sequence of morphologic patterns across the tumor 
boundary, such as shape, size, SUV values, and 
heterogeneities in a simple 2D map (Fig 1, bottom 
row). 
Handcrafted Feature  
       Our proposed shell feature was compared with 
the following five groups of handcrafted features: 9 
intensity features, 8 geometry features, 12 second 
order gray level co-occurrence matrix (GLCM) 
features, 5 high order neighborhood gray tone 
difference matrix (NGTDM) texture features, and a 
combination of these four types, for a total of 34. The 
features are described in Table 2 and calculation 
functions are provided in the Supplement. 
Prediction Model Development 
       To develop our prediction model we used a 
machine learning method based on support vector 
machine (SVM). SVM is a supervised learning model 
that can classify data through an optimal hyperplane 
representing the largest separation margin between 
two classes. Before being fed to SVM, the vectorized 
shell was applied by principal component analysis 
(PCA) to reduce the feature dimension. The reduction 
process is described in the Supplement. The 
predictive ability of the shell feature was compared 
with that of the other five features using ten random 
trails of 5-fold cross validation on both NSCLC and 
CC cohorts. Meanwhile, to handle the class 
imbalance problem, SVM was trained over 
preprocessed data by a synthetic minority over-
sampling technique (SMOTE). Accuracy, sensitivity, 
specificity, and area under the receiver operating 
characteristic curve (AUC) were used as evaluation 
metrics. The code was implemented in Matlab 
(version R2016a). 
Statistical Analysis 
      The difference in AUC performance between the 
shell feature and the other features was assessed by 
the Student’s t-test. The difference was considered 
statistically significant with a P value less than 0.05. 
The receiver operating characteristic (ROC) curve 
with 95% confidence interval is presented in Fig 2. 
Statistical analysis was performed with the Matlab 
statistical toolbox (version R2016a).  
 
RESULTS 
Clinical Characteristics  
       The demographic and clinical characteristics of 
patients in the NSCLC and CC cohorts are listed in 
Table 1. No significant difference in distant failure 
prevalence was observed between the two trials (ܲ ൌ 
0.917). During follow-up time, distant metastases 
were observed in 25% (12 of 48) of patients in the 
NSCLC cohort and 26.9% (14 of 52) in the CC 
cohort after radiotherapy.  
Comparison of Predictive Performance 
        The comparison between the shell feature and 
other features was performed on both NSCLC and 
CC cohorts through quantitative analysis (Table 3) 
and ROC graphing (Fig 2). AUC, sensitivity, 
specificity, and accuracy were the criteria used in the 
study. Definitions are given in the Supplement.  
       The shell feature showed the highest accuracy in 
predicting distant failure (Table 3). In the NSCLC 
cohort, the shell feature achieved an AUC of 0.82 (95% 
CI, 0.6632 to 0.9247) with 0.81 sensitivity, 0.80 
specificity, and 0.81 accuracy. For the other five 
features, the best result was observed for the GLCM 
texture as shown by 0.76 AUC (95% CI, 0.5528 to 
0.8905), 0.75 sensitivity, 0.74 specificity, and 0.75 
accuracy. Similarly, in the CC cohort the shell feature 
still achieved the best performance for all metrics, 
with 0.83 AUC (95% CI, 0.6559 to 0.9212), 0.81 
sensitivity, 0.80 specificity, and 0.80 accuracy. These 
results revealed that the shell feature had more 
discriminative capacity than the other features. Also, 
the difference in AUC performance between the shell 
feature and the other features was found to be 
significant (P < 0.005 for both features in both 
cohorts). 
       The ROC curves for different feature sets are 
illustrated in Fig 2. Similar results were obtained for 
NSCLC (Fig 2A) and CC (Fig 2B). The proposed 
shell feature, represented by the upper blue curve, is 
located close to the top left corner of the chart, 
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indicating on average a greater discriminative ability 
than the other methods. 
       The discriminative ability is indicated by 
representative 2D shell maps (Fig 3A and 3B) and 
vectorized shell feature matrixes (Fig 3C and 3D). 
The top row shows tumors without distant failure 
(Fig 3A) and the bottom row reports those with 
distant failure (Fig 3B). Pixels with higher SUV 
values are indicated in brighter colors, while lower 
values are shown in darker colors. As evident from 
the shell maps, distant failure-positive tumors show 
more heterogeneous boundary expression than the 
failure-negative ones. This finding may be attributed 
to the more active, varied, and potentially invasive 
cellular behavior of the tumor in the barrier 
microenvironment. The overall capability of the 
shell’s classification for the NSCLC and CC cohorts 
is indicated in Fig 3C and 3D. The rows in the 
matrixes are the vectorized shell’s sparse coefficients 
learned by the dictionary learning method.68 
Clustering characteristics can be seen on both 
cohorts, with features of the same class showing 
similar representation and features of different 
classes displaying distinct representations.  
 
DISCUSSION 
     The potential of tumor boundary as a predictive 
factor for distant failure was evaluated by the tumor 
shell, a PET-derived feature that allows us to detect 
its associations with metastasis within the 
microenvironment. The shell feature can be used to 
predict the outcome of SBRT for NSCLC patients 
and EBRT and concurrent chemotherapy followed 
with high-dose-rate ICBT for CC patients. 
      The tumor-host interface has been associated 
with metastasis because interactions between tumor 
cells and their microenvironment play an active part 
in tumor invasion and metastasis.69 However, to the 
best of our knowledge, few studies have targeted 
tumor boundaries in medical imaging for 
constructing risk models of metastasis.70,71 A recent 
study linked the morphology at the tumor-stroma 
interface to a multifractal metric, which derived from 
tumor outlines (excluding tumor internal tissue) on 
pathological images. The outline-based metric was 
found to be associated significantly (P < 0.001) with 
metastasis-related features, such as tumor border 
configuration and tumor budding grade, thereby 
verifying its prognostic and predictive efficacy for 
treatment response in colon cancer. 70 Similarly, in a 
lung cancer review, a fractal dimension of the tumor-
stroma interface was used to measure tumor 
progression.71 The study highlighted the use of 
radiological imaging, and found that the derived 
metric correlated with tumor growth and predicted 
treatment response.  71 Notably, the predictors in 
these studies were scores calculated from the contour 
lines of the tumor edge, whereas our method used 
the areas of the tumor boundary, where more 
minable information may be included. Besides, the 
calculation of the scores is a handcrafted processing, 
which is subject to human inconsistency and 
operator dependence. By contrast, our shell feature 
uses the original image information of the tumor 
edge directly and eliminates any calculation or 
feature selection procedure, thereby may be more 
scalable and generalizable.  
       The correlation between distant failure and 
radiomics features of the tumor edge is based on 
known biological processes that are associated with 
metastatic potential such as EMT and tumor budding. 
On the assumption that these findings are located at 
the tumor boundary, the shell feature was proposed 
to describe spatial morphology of the tumor 
periphery in relation to the likelihood of metastasis. 
Moreover, to the extent that these processes are 
present in other tumor types, it is likely that the shell 
feature may be used to predict the outcomes for other 
cancers.  
       Our study presents a few limitations, including 
the use of a small patient population and a 5-fold 
cross validation instead of an independent validation 
cohort.  Also, accumulating a serial of sub-shells (3D) 
into a 2D shell feature may lead to a loss of spatial 
complexity in the axial perspective. Finally, the 
influence of tumor boundary extension is not 
investigated in this paper.  
       In conclusion, the PET-derived shell feature 
revealed a relationship between tumor edge and 
distant failure, and can be used to facilitate early 
prediction of the radiotherapeutic response in 
NSCLC and CC patients. 
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TABLES & FIGURES
Table 1.  Characteristics of two cohorts of patients 
Characteristics  NSCLC Cohort    CC Cohort Distant failure (+)             Distant failure (‐)     Distant failure (+)             Distant failure (‐)      
Age, years           
    mean ± SD  69.9 ± 9.2  70.2 ± 10.2    41.6 ± 11.7       49.1 ± 11.3 
    Median (range)  69.5 (57.0‐89.0) 71.5 (54.0‐90.0)   38.2 (29.3‐70.9)       49.1 (26.2‐72.0) 
Ethnicity, No. (%)           
    Caucasian    9 (75.0)  27 (75.0) 6 (42.9) 12 (31.6) 
    Hispanic  0 (0)  1 (1.3)    2 (14.3)  15 (39.5) 
    African American  3 (25.0)  7 (19.4) 5 (35.7) 10 (26.3) 
    Asian  0 (0)  1 (1.3) 1 (7.1) 0 (0) 
    Other  0 (0)  0 (0)    0 (0)  1 (2.6) 
Clinical tumor size, mm, No. (%)          
    ≤ 10  1 (8.3)  0 (0)    0 (0)  1 (2.6) 
    11‐30  6 (50.0)  26 (72.2)   2 (14.3)  4 (10.6) 
    31‐50  5 (41.7)  9 (25.0)    9 (64.3)  20 (52.6) 
51‐70   0 (0)  1 (1.3)    2 (14.3)  9 (23.6) 
   > 71  0 (0)  0 (0)    1 (7.1)  4 (10.6) 
Histology, No. (%)           
    Adenocarcinoma  6 (50.0)  17 (47.3)    1 (7.1)  4 (10.6) 
    Squamous cell carcinoma  5 (41.7)  12 (33.3)    11 (78.6)  33 (86.8) 
    Other  1 (8.3)  7 (19.4)    2 (14.3)  1 (2.6) 
Stage, No. (%)           
  IA  5 (41.7)  30 (83.3)    0 (0)  0 (0) 
  IB  7 (58.3)  6 (16.7)    4 (28.6)  12 (31.6) 
  IIA  0 (0)  0 (0)    1 (7.1)  3 (7.9) 
  IIB  0 (0)  0 (0)    7 (50.0)  15 (39.5) 
  IIIB  0 (0)  0 (0)    0 (0)  6 (15.8) 
  IVA  0 (0)  0 (0)    2 (14.3)  2 (5.2) 
NOTE. Stages in NSCLC and CC are determined by the TNM and Federation of Gynecology and Obstetrics (FIGO) staging system, respectively.  
Abbreviations: NSCLC, non‐small cell lung cancer; CC: cervix cancer; SD: standard deviation. 
 
 
Table 2.  Types of handcrafted features 
Histogrambased image  
intensity   Geometry   GLCM based texture   NGTDM based texture  
Minimum  Volume  Energy  Coarseness 
Maximum  Major diameter  Entropy  Contrast* 
Mean  Minor diameter  Correlation  Busyness 
Stand deviation  Eccentricity  Contrast*  Complexity 
Sum  Elongation  Texture Variance  Texture Strength 
Median  Orientation  Sum‐Mean   
Skewness  Bounding Box Volume  Inertia   
Kurtosis  Perimeter  Cluster Shade   
Variance    Cluster tendency   
    Homogeneity   
    Max‐Probability   
    Inverse Variance   
NOTE. *Contrast: Different calculation methods were employed in GLCM and NGTDM, though the same names are indicated. 
Abbreviations: GLCM, Gray level co‐occurrence matrix; NGTDM, Neighborhood gray tone difference matrix. 
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Table 3.  Prediction performance of features with respect to distant failure  
cohort  features  Accuracy  Sensitivity  Specificity  AUC       95% CI     P value 
NSCLC   Intensity  0.70 ± 0.01  0.70 ± 0.02  0.69 ± 0.01  0.73 ± 0.02  [0.5615,0.8613]       .0002 
  Geometry  0.68 ± 0.01  0.65 ± 0.06  0.70 ± 0.04  0.65 ± 0.01  [0.4861,0.8009]         .0001 
  GLCM texture  0.75 ± 0.03  0.75 ± 0.03  0.74 ± 0.03  0.76 ± 0.02  [0.5528,0.8905]       .0044 
  NGTDM texture  0.68 ± 0.03  0.70 ± 0.06  0.65 ± 0.02  0.73 ± 0.03  [0.5139,0.8783]       .0015 
  Combination  0.73 ± 0.04  0.72 ± 0.02  0.71 ± 0.03  0.76 ± 0.02  [0.5887,0.8796]       .0025 
  Shell   0.81 ± 0.03  0.81 ± 0.02  0.80 ± 0.03  0.82 ± 0.03  [0.6632,0.9247]        − 
CC  Intensity  0.72 ± 0.02  0.71 ± 0.03  0.75 ± 0.03  0.69 ± 0.01  [0.4743,0.8533]       .0003 
  Geometry  0.71 ± 0.04  0.71 ± 0.01  0.71 ± 0.04  0.71 ± 0.01  [0.4891,0.8590]       .0006 
  GLCM texture  0.75 ± 0.02  0.80 ± 0.02  0.73 ± 0.02  0.76 ± 0.04  [0.5427,0.8981]       .0015 
  NGTDM texture  0.72 ± 0.04  0.71 ± 0.02  0.74 ± 0.04  0.74 ± 0.03  [0.5396,0.8524]       .0002 
  Combination  0.72 ± 0.03  0.75 ± 0.05  0.73 ± 0.03  0.73 ± 0.02  [0.5519,0.8813]    < .0001 
  Shell   0.80 ± 0.04  0.81 ± 0.02  0.80 ± 0.04  0.83 ± 0.02  [0.6559,0.9212]         − 
NOTE. “Combination” refers to the combined four types of features, i.e., intensity, geometry, GLCM texture and NGTDM texture; 95% CI and 
P value are both derived from values of AUC; P value measures the statistical AUC difference between each group of handcrafted features 
and shell feature.  
Abbreviations: AUC, the area under a characteristic operation curve; CI, confidence interval. 
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   Fig 1.  Shell feature extraction workflow. (A) Series of axial PET slices of one patient. (B) Series of patches (red windows in A) including tumors 
are cropped from each slice in A.  (C). Series of sub‐shells derived from adjacent two patches in B. (D). Shell feature, with grayscale image left 
and Heatmap image right.  
 
 
                    
Fig 2.  Receiver operating characteristic (ROC) curves of shell feature and other five groups of handcrafted features. (A) NSCLC cohort. (B)CC 
cohort. ROC curves depict  the classification ability of  the binary SVM model  in  terms of predictive  feature and observed outcome of distant 
failure  under  varied  discrimination  threshold.  The  x‐axis  represents  the  false  positive  rate  and  is  calculated  as  (1‐specificity).  The  y‐axis 
represents the true positive rate by sensitivity.  A larger area under the curve indicates better prediction. 
 
A 
B 
C 
D 
A  B
  PET slices
   Patches 
cropped  from  
       slices 
    Sub‐Shells 
      between      
adjacent patches 
                     Shell  
         (Summed sub‐shells) 
…
…
…
9 
 
 
 
    Fig 3.  The shell feature has the discriminative ability to detect distant failure (DF)‐negative and ‐positive tumors. (A) (B) are representative 
examples of  2D  shell  in  terms of  structure  heterogeneity.  (A) NSCLC  cases.  (B)  CC  cases.  In  each  cohort,  the  shell  feature  (third  column)  is 
computed from a series of slices (second column) in the tumor volume (first column), with the top row showing tumors without distant failure 
and  the  bottom  row  showing  tumors  with  distant  failure.  As  shown,  tumors  with  distant  failure  present  more  complicated  morphologic 
patterns.  (C)  (D) are  feature matrixes of  the whole patients, where each  row corresponds  to a patient, and each column corresponds  to an 
element  of  the  feature.  (C) NSCLC  cases.  (D)  CC  cases.  These  features  are  sparse  coefficients  learned  from  the original  vectorized  shells  by 
dictionary learning method. These feature matrixes exhibit clustering characteristics for (DF)‐positive and ‐negative tumors. 
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